



NDA 20-702/S-047

Pfizer Inc., US Agent for
Pfizer Ireland Pharmaceuticals
Attention: Madeleine M. Carlson
Director, US Regulatory Affairs
235 East 42nd Street
New York, NY 10017

Dear Ms. Carlson:

Please refer to your supplemental new drug application dated May 4, 2006, received, May 5, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lipitor (atorvastatin calcium) Tablets.

We acknowledge receipt of your submissions dated February 22 and 23(email), 2007.

This supplemental new drug application provides for new indications, based on the results of the Treating to New Targets Study (TNT), for the use of atorvastatin in adult patients with clinically evident coronary heart disease to reduce the risk of non-fatal myocardial infarction, fatal and non-fatal stroke, angina, revascularization procedures, and hospitalization for congestive heart failure.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text. Submit content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text which you submitted February 23, 2007. Upon receipt and verification, we will transmit that version to the National Library of Medicine for posting on the DailyMed website.

The final printed labeling (FPL) must be identical to the enclosed draft labeling.

Please submit either an electronic version or 20 paper copies of the FPL as soon as it is available (no more than 30 days after it is printed). If paper copies are submitted, individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-702/S-047.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301)796-1295.

Sincerely,

{See appended electronic signature page}

Mary Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
(DMEP)
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Eric Colman
3/2/2007 11:34:28 AM
Eric Colman for Mary Parks